200 related articles for article (PubMed ID: 11744479)
1. Nilutamide: possible utility as a second-line hormonal agent.
Desai A; Stadler WM; Vogelzang NJ
Urology; 2001 Dec; 58(6):1016-20. PubMed ID: 11744479
[TBL] [Abstract][Full Text] [Related]
2. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
5. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogen withdrawal syndrome with nilutamide.
Huan SD; Gerridzen RG; Yau JC; Stewart DJ
Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
8. Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.
Todd NF; Lieberman R; Gulley JL; Dahut W; Arlen PM
Am J Ther; 2005; 12(2):172-4. PubMed ID: 15767834
[TBL] [Abstract][Full Text] [Related]
9. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
Joyce R; Fenton MA; Rode P; Constantine M; Gaynes L; Kolvenbag G; DeWolf W; Balk S; Taplin ME; Bubley GJ
J Urol; 1998 Jan; 159(1):149-53. PubMed ID: 9400459
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogens as monotherapy for prostate cancer.
Schröder FH
Eur Urol; 1998; 34 Suppl 3():12-7. PubMed ID: 9854190
[TBL] [Abstract][Full Text] [Related]
11. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Sarosdy MF
Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
[TBL] [Abstract][Full Text] [Related]
12. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
[TBL] [Abstract][Full Text] [Related]
13. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Arlen PM; Gulley JL; Todd N; Lieberman R; Steinberg SM; Morin S; Bastian A; Marte J; Tsang KY; Beetham P; Grosenbach DW; Schlom J; Dahut W
J Urol; 2005 Aug; 174(2):539-46. PubMed ID: 16006888
[TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
[TBL] [Abstract][Full Text] [Related]
19. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
